Search Results
Reductil marketing authorisation suspended
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the marketing authorisation for Reductil (sibutramine) is suspended across Europe following a review completed by the Eur...
Micardis licence extended
Micardis (telmisartan) can now be prescribed for the prevention of cardiovascular morbidity in patients with manifest atherothrombotic cardiovascular disease (history of coronary heart disease, str...
Tritace in renal disease
Tritace (ramipril) is now licensed for the treatment of incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria, manifest glomerular diabetic nephropathy as defined...
New blood glucose meter
Roche has launched a new blood glucose meter, the Mobile meter. The meter comes with a detachable Fastclix finger pricker for use with Fastclix lancets. Designed to minimise the handling of indivi...
New interleukin inhibitor
Novartis has launched a new interleukin inhibitor, Ilaris (canakinumab) for the treatment of cryopyrin-associated periodic syndromes (CAPS).
Care Virasoothe Cooling Gel
Care Virasoothe Cooling Gel is available for the symptomatic relief of chickenpox. The glycerol-containing gel cools and soothes the affected areas to help relieve itching. It is suitable for use...
Baby Nose-Clear aspirator
A nasal aspirator is available on prescription for use in infants from birth. The non-invasive, drug-free aspirator relieves nasal congestion by physically removing mucus, allowing clearer breathing,...
More good news for patients awaiting MS tablet
Promising results from placebo-controlled trials of two oral immunosuppressants for relapsing-remitting multiple sclerosis have been published in the New England Journal of Medicine.
Resolor launched for chronic constipation
Resolor (prucalopride) is a new treatment for women with chronic laxative-resistant constipation.
NSAID/PPI combination therapy launched for rheumatoid arthritis
Axorid is a combination of ketoprofen and omeprazole that is indicated for the treatment of rheumatoid arthritis, ankylosing spondylitis and osteoarthritis in patients at risk of NSAID-related GI dama...
Vaccine for Japanese encephalitis
Novartis Vaccines has launched Ixiaro for active immunisation of adults against Japanese encephalitis.
Januvia approved as add-on to insulin treatment
Januvia ( sitagliptin ) can now be prescribed as an add-on to insulin (with or without metformin ) for patients with type II diabetes in whom diet and exercise, plus a stable dose of insulin, do...
Methylphenidate warnings updated
Prescribing information for methylphenidate is being updated following a review of the drug's safety conducted by the EMEA earlier this year. The agency concluded that the benefits of medicines co...
MHRA updates warfarin safety advice
Safety issues surrounding the use of warfarin have been reviewed by the MHRA. As detailed in the agency's Public Assessment Report , the drug's contraindications have been tightened to include us...
Ciclosporin: prescribe by brand
Ciclosporin should be prescribed and dispensed by brand, according to new advice issued by the MHRA. As a critical-dose drug, ciclosporin has a narrow therapeutic window; consequently, even minor...
Procoralan now licensed for use with beta-blockers
Procoralan (ivabradine) may now be prescribed in combination with beta-blockers in patients with chronic stable angina inadequately controlled with an optimal beta-blocker dose and whose heart rate...
Rheumatoid arthritis antibody succeeds in late-stage trial
The first Phase III trial of ocrelizumab has met its primary efficacy end point in patients with methotrexate-resistant rheumatoid arthritis.
Deleted products 2009
The following products were discontinued from the UK market during 2009. The list below states the month they were withdrawn from MIMS.
Sinemet supply problems
MSD has warned that the availability of Sinemet (levodopa/carbidopa) will be reduced from late 2009 until 2011. The global shortage of the Parkinson s disease treatment, which is due to a change i...
Withdrawal of Alupent
The short-acting bronchodilator orciprenaline sulphate ( Alupent ) is to be withdrawn over the next year, following an unfavourable risk-benefit analysis by the MHRA . It concluded that the adverse...
MIMs Drug Search
Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.
